Xin Yu – NVIDIA Technical Blog News and tutorials for developers, data scientists, and IT admins 2024-12-12T19:38:30Z http://www.open-lab.net/blog/feed/ Xin Yu <![CDATA[In-Silico Antibody Development with AlphaBind Using NVIDIA BioNeMo and AWS HealthOmics]]> http://www.open-lab.net/blog/?p=92757 2024-12-12T19:38:30Z 2024-12-03T18:00:00Z Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range...]]>

Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range of diseases, from cancer to autoimmune disorders. Their specificity reduces the likelihood of off-target effects, making them safer and often more effective than small-molecule drugs for complex conditions. As a result…

Source

]]>
Xin Yu <![CDATA[Spotlight: Montai Builds a Multimodal AI Platform for Drug Discovery Using NVIDIA NIM Microservices]]> http://www.open-lab.net/blog/?p=89334 2024-10-23T23:37:06Z 2024-09-26T16:00:00Z Drug discovery aims to develop new therapeutic agents that effectively target diseases while minimizing side effects for patients. Using multimodal data��such...]]>

Drug discovery aims to develop new therapeutic agents that effectively target diseases while minimizing side effects for patients. Using multimodal data—such as molecular structures, cellular images, sequences, and unstructured data—can be highly valuable in identifying novel and safe drug candidates. Yet, creating multimodal AI models for computer-aided drug discovery is challenging.

Source

]]>
���˳���97caoporen����